新闻
每一条新闻均可对照信源核实
Naprod的新闻页面只发布可独立核实的报道：监管机构自身的登记名录、具名的行业出版物，或标注日期的公司公告。此处不会将新闻稿包装成新闻发布。
自2026年1月以来共记录4条报道，其中包括1项经第三方核实的监管里程碑：ANVISA于2026年1月完成的GMP续签，由Pharma India Magazine报道。
Featured
ANVISA Renews GMP Certification for Naprod's Tarapur Sterile-Oncology Facility
Brazil's national health regulatory authority renewed Good Manufacturing Practice certification for Naprod's Tarapur plant in January 2026, keeping the sterile oncology injectables facility qualified to supply the Brazilian and wider Mercosur market.
Source: Pharma India Magazine and Medical Dialogues
Read the full story →Dated trail
Every other entry, dated and sourced
Company announcements are labeled as such and are not presented as independently verified unless they carry a named third-party source.
-
Naprod's Tarapur Register: 15 Manufacturing Accreditations Now Confirmed From Certificates on File
Following the January 2026 ANVISA renewal, Naprod's accreditation register now shows 15 of its 21 international certifications confirmed from the issued certificate held on file, with 6 more being digitized for publication.
Naprod Life Sciences (company announcement) -
Naprod to Showcase Oncology and Lyophilized Injectables at CPHI South East Asia 2026
Naprod Life Sciences will exhibit its oncology, injectable, and lyophilized formulation capabilities at CPHI South East Asia 2026 in Bangkok (Booth B31, 8–10 July 2026), inviting distributors and partners to discuss supply and partnership opportunities.
Naprod Life Sciences (LinkedIn) -
Naprod Appoints Smita Kadam as DGM, International Business
Naprod Life Sciences announced the appointment of Smita Kadam as Deputy General Manager, International Business, bringing 15 years of international business-development experience to strengthen the company's expansion across Latin America.
Naprod Life Sciences (LinkedIn) -
Naprod Reaffirms Oncology Supply Continuity Amid Platinum Raw-Material Constraints
Naprod Life Sciences stated its commitment to uninterrupted supply of platinum-based oncology injectables, including Cisplatin and Carboplatin, as industry-wide raw-material constraints affect availability, focusing on supply continuity for healthcare institutions.
Naprod Life Sciences (LinkedIn) -
Naprod Joins Pharma Eurasia 2026 in Tashkent to Expand Across CIS Markets
Naprod Life Sciences exhibited at Pharma Eurasia 2026 at Tashkent Pharma Park, Uzbekistan (Stall D15, 20–22 May 2026), connecting with partners across the Eurasian pharmaceutical market.
Naprod Life Sciences (LinkedIn) -
Naprod Details Oncology Injectable Manufacturing Capacity at Tarapur
Company update outlining current lyophilized and liquid oncology injectable capacity at the Tarapur site, alongside the facility's broader dosage-form output.
Naprod Life Sciences (company announcement)
时效性承诺
经核实后才发布的新闻页面，而非仅发布了事
此新闻板块在原网站上自2019年起处于停更状态。此后，每条记录均标注发布日期、信源，及核实标记。第三方报道的内容，只有在对照具名媒体或监管机构登记名录核实后，才会标注为已核实；公司自有信源的公告将明确标注为公司公告，绝不与独立报道混同呈现。除非可追溯至具名、可核实的信源，否则不会在此发布新闻稿、博客文章、获奖宣称或质量项目名称。
Pending approval Historical news content from before this rebuild (pre-2026) was not recoverable from available source material and is not represented here.
面向媒体与合作伙伴
媒体资料包与新闻联系人
可下载的媒体资料包（公司背景资料、Tarapur基地情况说明及经批准的标志素材）正在准备中。媒体及法规事务相关咨询可发送至Naprod的质量与法规事务团队；具名的新闻联系人将在公司确认后于此发布。
Pending approval Media kit assets and a named press contact are PENDING APPROVAL; this section will link directly to the kit and list a contact once the company confirms them.